According to the latest market research study released by Technavio, the global metabolic disorders therapeutics market is expected to grow at a CAGR of close to 5% during the forecast period 2016-2020.
This market research report by Technavio provides an in-depth analysis of the market in terms of revenue and emerging market trends. The report also includes an up-to-date analysis and forecasts for various market segments and all geographical regions.
Click here to request a free sample of this report
Technavio research analysts categorize the global metabolic disorders therapeutics market based on disease type:
Global metabolic disorders therapeutics market share by product type 2015
|
Diabetes |
63.77% |
|
Hypercholesterolemia |
27.41% |
|
Lysosomal Storage |
7.75% |
|
Obesity |
1.07% |
Source: Technavio
Diabetes drugs market
The global metabolic disorders therapeutics market by diabetes drugs was valued at almost $45 billion in 2015 and post a CAGR of more than 7% by 2020. Diabetes mellitus is a metabolic condition in which a patient’s blood glucose levels remains high. The different types of diabetes are type 1 diabetes, type 2 diabetes, and gestational diabetes. Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels; and in this condition, the immune system is activated against self-insulin-producing cells. This type of diabetes hampers the body’s ability to produce insulin and disrupts blood glucose homeostasis.
“The most common form of diabetes mellitus is Type 2 diabetes, and in this condition, the insulin is produced in the body but not absorbed by the cells. As a result, glucose levels in the body increase substantially. The high prevalence of these diseases across emerging countries like India and China will lead to the development of metabolic disorders therapeutics market,” says Barath Palada, a lead analyst at Technavio for research on cardiovascular and metabolic disorders.
Hypercholesterolemia drugs market
The global metabolic disorders therapeutics market by hypercholesterolemia drugs was valued at around $19 billion in 2015 and will grow at a CAGR of more than 6% by 2020. This condition is characterized by very high levels of total cholesterol and LDL in the blood of a person and can lead to cardiovascular diseases (CVDs) like atherosclerosis and stroke. The different types of hypercholesterolemia include familial hypercholesterolemia (FH), heterozygous familial hypercholesterolemia (HeFH), and homozygous familial hypercholesterolemia (HoFH). FH is the hereditary form of hypercholesterolemia that is characterized by elevated levels of total cholesterol and LDL.
Lysosomal storage drugs market
The global metabolic disorders therapeutics market by lysosomal storage drugs was valued at about $5 billion in 2015 and will post a CAGR of almost 10% by 2020. Lysosomal storage diseases fall under a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins and proteins required for normal post-translational modification (PTM) of lysosomal enzymes. Gaucher disease is the most prevalent form of lysosomal storage disease. Type 1 Gaucher disease is the most generic form and occurs in approximately 90% of the cases. Type 1 Gaucher disease is non-neurological, whereas type 2 and type 3 are the acute neurological and subacute neurological forms.
Anti-obesity drugs market
The global metabolic disorders therapeutics market by anti-obesity drugs was valued at almost $1 billion in 2015 and will grow at a CAGR of around 20% by 2020. Obesity is a medical condition in which surplus body fat gets accumulated and can have a detrimental effect on the health of an individual and individuals suffering from obesity, especially when they weigh 20% or more than their ideal body weight. This medical condition is linked to increased risk of illness, physical disability, and death and even though anti-obesity drugs are available in the market, their efficacy is restricted to maintenance of weight-loss rather than cure.
The top leading vendors operating in the global metabolic disorders therapeutics market are:
- AstraZeneca
- Eli Lilly and Company
- Merck & Co.
- Novo Nordisk
- Sanofi
Other prominent vendors in the market include AbbVie, Actelion Pharmaceuticals, Adocia, Aegerion Pharmaceuticals, Akros Pharma, Alnylam Pharmaceuticals, Amarin, nAmgen, Amicus Therapeutics, Arbutus Biopharma, Arena Pharmaceuticals, Astellas Pharma, Atheronova, Aurobindo Pharma, Baxalta, Belrose Pharma, BHV Pharma, Biocon, Biodel, BioMarin, Bionaturis, Biosidus, Biospherics, Boehringer Ingelheim, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Chipscreen Biosciences, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, ConjuChem, CureDm, CymaBay Therapeutics, Daewoong, Daiichi Sankyo, Dance Biopharm, DiaMedica, Diamyd Therapeutics, Diasome Pharmaceuticals, DiaVacs, Dong-A ST, Eisai, Elcelyx Therapeutics, Esperion Therapeutics, Exsulin, F. Hoffmann-La Roche, Gan & Lee Pharmaceuticals, Generex Biotechnology, Genfit, GlaxoSmithKline, HanAll BioPharma, Hanmi Pharmaceutical, Hua Medicine, Iltoo Pharma, Intarcia Therapeutics, InteKrin Therapeutics, Intrexon, Ionis Pharmaceuticals, Islet Sciences, ISU Abxis, Janssen Pharmaceuticals, Japan Tobacco, JCR Pharmaceuticals, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kamada, KinDex Pharmaceuticals, Kissei, Kotobuki, Kowa Company, Laboratoires SMB, Lexicon Pharmaceuticals, Ligand Pharmaceuticals, Living Cell Technologies, Livzon, LIXTE Biotechnology, Lupin, MacroGenics, Madrigal Pharmaceuticals, MannKind, MedImmune, Melior Pharmaceuticals, Merrion Pharmaceuticals, Merz Pharmaceuticals, Metabolic Solutions Development Company, Mitsubishi Tanabe Pharma, Mylan, Neothetics, Neuraltus Pharmaceuticals, NGM Biopharmaceuticals, NGM Biopharmaceuticals, Norgine BV, Novartis, NuSirt Biopharma, Oramed, Orexigen Therapeutics, Osiris Therapeutics, Peptron, Perle Biosciences, Pfizer, PhaseBio Pharmaceuticals, Poxel, Protalix Biotherapeutics, Raptor, Recordati, Regeneron Pharmaceuticals, REGENX BioSciences, REGiMMUNE, Rhythm Pharmaceuticals, Saniona, Santaris Pharma, Sanwa Kagaku Kenkyusho, Serometrix, Shionogi, Shire, Sigma-Tau, Sirona Biochem, Strongbridge Biopharma, SUN Pharma, Takeda, Teva, Thera technologies, Theracos, Toleranzia, Tolerion, Torrent Pharmaceuticals, Transition Therapeutics, UCB, Utrecht Holdings, VeroScience, Vivus, vTv Therapeutics, XBiotech, Xeris Pharmaceuticals, XOMA, Zafgen, and Zydus Cadila.
A more detailed analysis is available in the Technavio report titled, ‘Global Metabolic Disorders Therapeutics Market 2016-2020’. Technavio also customizes reports by other regions and specific segments upon request.
Other related reports:
- Global Gastrointestinal Therapeutics Market 2016-2020
- Global Musculoskeletal Disorders Therapeutics Market 2016-2020
- Global Gout Therapeutics Market 2016-2020
To read more press releases- click here.
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
